GlassScriptPhysician profile
Jared P Wilson
NPI 1699868927
$3,603.64
in general payments reported to CMS, 2019-2025
26 companies · $965 in 2025
The $965 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $942 · 2023: $673 · 2024: $633 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.28 |
| Education | $245.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.84 | 2021-2025 | |
| Janssen Biotech, INC. | $459.18 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $400.30 | 2021-2025 | Dupixent |
| Genzyme Corporation | $311.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $294.81 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $215.61 | 2022-2024 | Vtama |
| Ucb, INC. | $180.13 | 2022-2025 | Bimzelx |
| Pfizer INC. | $167.32 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $121.27 | 2021-2022 | |
| Leo Pharma INC. | $111.88 | 2022-2025 | Adbry |
| Amgen INC. | $90.22 | 2021-2023 | Otezla |
| Lilly USA, LLC | $68.96 | 2021-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $56.61 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $48.22 | 2023-2025 | |
| Incyte Corporation | $45.90 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $39.87 | 2025 | Vtama |
| Organogenesis INC. | $35.47 | 2024 | Nushield |
| Kerecis Limited | $34.25 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.51 | 2023 | Spevigo |
| Janssen Scientific Affairs, LLC | $26.60 | 2022 | |
| Botanix Sb INC | $22.88 | 2025 | Sofdra |
| Biofrontera INC. | $22.50 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $22.28 | 2023 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $20.17 | 2022 | |
| Lnhc, INC | $14.30 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.